Compare Sysmex Corp. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 11.89%
- Healthy long term growth as Net Sales has grown by an annual rate of 10.99%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 47.97
2
Negative results in Jun 25
3
With ROE of 12.00%, it has a attractive valuation with a 3.18 Price to Book Value
4
Majority shareholders : Non Institution
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 987,969 Million (Large Cap)
27.00
NA
0.00%
-0.09
10.07%
2.05
Revenue and Profits:
Net Sales:
105,731 Million
(Quarterly Results - Jun 2025)
Net Profit:
4,476 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.45%
0%
-12.45%
6 Months
-39.6%
0%
-39.6%
1 Year
-46.99%
0%
-46.99%
2 Years
-42.42%
0%
-42.42%
3 Years
-82.73%
0%
-82.73%
4 Years
-86.3%
0%
-86.3%
5 Years
-87.45%
0%
-87.45%
Sysmex Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.99%
EBIT Growth (5y)
10.47%
EBIT to Interest (avg)
47.97
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
1.00
Tax Ratio
31.55%
Dividend Payout Ratio
37.18%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
21.85%
ROE (avg)
11.89%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
3.18
EV to EBIT
15.94
EV to EBITDA
11.10
EV to Capital Employed
3.44
EV to Sales
2.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
21.57%
ROE (Latest)
12.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
105,731.00
111,946.00
-5.55%
Operating Profit (PBDIT) excl Other Income
20,523.00
26,454.00
-22.42%
Interest
909.00
590.00
54.07%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4,476.00
10,984.00
-59.25%
Operating Profit Margin (Excl OI)
92.30%
148.90%
-5.66%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -5.55% vs 17.40% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -59.25% vs 28.30% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
508,643.00
461,510.00
10.21%
Operating Profit (PBDIT) excl Other Income
128,708.00
113,185.00
13.71%
Interest
2,995.00
2,332.00
28.43%
Exceptional Items
-3,731.00
149.00
-2,604.03%
Consolidate Net Profit
53,576.00
49,774.00
7.64%
Operating Profit Margin (Excl OI)
176.30%
167.50%
0.88%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 10.21% vs 12.43% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 7.64% vs 8.86% in Mar 2024
About Sysmex Corp. 
Sysmex Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






